ArticleTranslational vision science & technology2021

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema.

Pravin U Dugel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.